Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells

Cancer Science
Keizo MisumiSatoshi Tashiro

Abstract

The epidermal growth factor receptor (EGFR) tyrosine kinase signaling pathways regulate cellular activities. The EGFR tyrosine kinase inhibitors (EGFR-TKIs) repress the EGFR pathway constitutively activated by somatic EGFR gene mutations and have drastically improved the prognosis of non-small-cell lung cancer (NSCLC) patients. However, some problems, including resistance, remain to be solved. Recently, combination therapy with EGFR-TKIs and cytotoxic agents has been shown to improve the prognosis of NSCLC patients. To enhance the anticancer effects of EGFR-TKIs, we examined the cross-talk of the EGFR pathways with ataxia telangiectasia-mutated (ATM) signaling pathways. ATM is a key protein kinase in the DNA damage response and is known to phosphorylate Akt, an EGFR downstream factor. We found that the combination of an ATM inhibitor, KU55933, and an EGFR-TKI, gefitinib, resulted in synergistic cell growth inhibition and induction of apoptosis in NSCLC cell lines carrying the sensitive EGFR mutation. We also found that KU55933 enhanced the gefitinib-dependent repression of the phosphorylation of EGFR and/or its downstream factors. ATM inhibition may facilitate the gefitinib-dependent repression of the phosphorylation of EGFR an...Continue Reading

References

Oct 26, 1999·Current Biology : CB·A BlasinaC H McGowan
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Jul 31, 2004·Science·Raffaella SordellaJeffrey Settleman
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Nov 18, 2004·The Journal of Biological Chemistry·Juan Guinea ViniegraRicardo Sánchez-Prieto
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Sep 29, 2005·PLoS Medicine·Heidi GreulichMatthew Meyerson
Mar 14, 2007·Cell Cycle·Yu-Wen Zhang, George F Vande Woude
Jul 5, 2007·Differentiation; Research in Biological Diversity·Floriana MorgilloFortunato Ciardiello
Mar 14, 2008·The New England Journal of Medicine·Fortunato Ciardiello, Giampaolo Tortora
May 28, 2009·Human Mutation·Raquel BlancoMontse Sanchez-Cespedes
Aug 14, 2009·The FEBS Journal·Takeshi NagashimaMariko Hatakeyama
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Mar 4, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chung-Yu ChenPan-Chyr Yang
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nobuyuki KatakamiNobuyuki Yamamoto
Jul 16, 2013·Oncogene·C A Cremona, A Behrens
Feb 4, 2014·Cancer Science·Noriko Hosoya, Kiyoshi Miyagawa
Feb 12, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S SugawaraUNKNOWN North East Japan Study Group and Tokyo Cooperative Oncology Group

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.